ArticleF1000Research2026
Isolation of
Article in F1000Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting. This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Methods: The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device. Results: The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm Conclusions: This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.